Feb 7th 2023 - Mar 21st 2023
- Timo grimmer is in the team - All endpoints of ... See more
Anavex's A2-73 Blarcamesine's trial result... See more
Feb 7th 2023 - Mar 21st 2023
$SAVA “Treatment also eased depression and dementi... See more
Simufilam reduced dementia-related behavior at 9 m... See more
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 7th 2023 - Mar 21st 2023
They voluntarily suspended phase 3 bc they are see... See more
$PALI phase 2 coming WOOOOO!! !
- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.
Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.
$AVXL amazing avxl still in singke digits after a supposedly amazing “pivotal” trial readout 🤦🏻♂️🤦🏻♂️🤦🏻♂️😂😂😂
$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.
$AVXL Australia trial data meets the gold standard.
The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.
2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.
This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.
Sava has potential and the phase 3 results will show the truth.
$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”
Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.
The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.
$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.
$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.
$SAVA , VERA announced positive phase 2b results meeting primary end point.
My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients
